开拓药业核心产品KX-826(福瑞他恩)与米诺地尔联合治疗男性脱发效果显著,优于米诺地尔单药,引发市场关注。KX-826是雄激素受体拮抗剂,曾历经挫折,现以化妆品形式上市并贡献营收,联用研究再显成效。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.